心衰住院患者食物补充干预的随机临床试验
这项开放标签析因随机临床试验纳入150例出院14天内的心衰住院患者,按1:1:1随机分为医疗定制餐食组、新鲜蔬果组或常规照护组,随访12周。食物补充完成率为93.6%,保留率为96.0%,但食物补充组与常规照护组在90天心衰再入院或急诊就诊的主要临床终点方面无显著差异。
要点
- 食物补充干预在近期心衰住院患者中可行且接受度良好。
- 食物补充未显著降低90天心衰再入院或急诊就诊风险。
- 以医疗参与为条件的配送与无条件配送在心衰事件风险方面无差异。
核心结论
- 在近期心衰住院患者中,90天食物补充干预可行且接受度良好。
- 食物补充与主要临床结局改善无显著相关性。
- 以医疗参与为条件的食物补充配送与无条件配送在心衰事件方面无差异。
研究设计与样本
- 开放标签析因随机临床试验,2024年4月至2025年10月在得克萨斯州达拉斯2家医院开展。
- 纳入150例心衰住院且出院14天内入组的患者,排除既往心脏移植、左心室辅助装置或出院时需正性肌力药物支持者。
- 按1:1:1随机分为医疗定制餐食组、新鲜蔬果组或常规照护组,食物补充组再按1:1随机分为条件配送与无条件配送。
- 随访12周。150例入组者中2例因临床恶化退出,1例死亡,6例失访,均纳入意向治疗分析。
主要发现
- 食物配送完成率为93.6%,总体保留率为96.0%。
- 医疗定制餐食组报告的平均食用依从性为每周4.7天(SD 2.4),新鲜蔬果组为每周5.5天(SD 2.3)。
关键数值与推荐
- 在食物补充组中,条件配送与无条件配送在心衰事件风险方面无显著关联。
- 基线中位左心室射血分数为35%(IQR 25.0-54.0),基线中位KCCQ-CSS为56.6(IQR 36.8-72.9)。
- 79例(52.7%)参与者存在食物不安全。
- 主要临床终点定义为90天随访期间心衰再入院或心衰急诊就诊。
临床怎么用
- 对近期心衰住院患者提供食物补充在实施层面可行,但在常规推广前需进一步验证其临床获益。
- 新鲜蔬果在可接受性方面优于医疗定制餐食,可作为食物补充方案的优先考虑形式。
局限性
- 开放标签设计可能存在实施偏倚,且主要临床结局为探索性分析。
- 样本量为150例,事件数较少,主要临床终点检验效能有限。
- 研究在单一城市2家医院开展,结果外推至其他人群和地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low-quality dietary intake is associated with adverse heart failure (HF) outcomes, yet evidence evaluating food-as-medicine interventions that supply high-quality dietary content is limited. OBJECTIVE: To determine the feasibility of providing food supplementation with medically tailored meals or fresh produce and explore the association of food supplementation vs usual care with clinical outcomes in patients recently hospitalized with HF and whether it differs by conditioning food supplementation to health care engagement. DESIGN, SETTING, AND PARTICIPANTS: This open-label factorial randomized clinical trial was conducted between April 2024 and October 2025 at 2 hospitals in Dallas, Texas. The study included patients who were hospitalized for HF and enrolled within 14 days of discharge, excluding those with prior heart transplant, a left ventricular assist device, or inotropic support at discharge; current enrollment in meal delivery programs; and inability to receive home deliveries. Participants were followed up with for 12 weeks. Of 150 participants enrolled, 2 were withdrawn due to clinical deterioration, 1 died, and 6 were lost to follow-up; all were included in the intention-to-treat analysis. INTERVENTIONS: Participants were randomized 1:1:1 to medically tailored meals, fresh produce, or usual care. Those receiving food supplementation underwent secondary 1:1 randomization to conditional (linked to clinic attendance and medication fills) vs unconditional delivery. MAIN OUTCOMES AND MEASURES: Implementation outcomes included delivery completion, adherence, and acceptability and exploratory clinical outcomes. The primary clinical outcome was defined as readmission for HF or emergency department (ED) visits for HF over 90-day follow-up. Secondary clinical outcomes included a win-ratio-based hierarchical composite (all-cause death, total HF hospitalizations or ED visits, and ≥10-point Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score [KCCQ-CSS] improvement). RESULTS: Among 150 participants (median [IQR] age, 59.5 [52.0-66.0] years; 91 [60.7%] male), the baseline median (IQR) left ventricular ejection fraction was 35% (25.0-54.0), the baseline median (IQR) KCCQ-CSS was 56.6 (36.8-72.9), and 79 (52.7%) had food insecurity. Food delivery completion was 93.6% with a mean (SD) reported consumption adherence of 4.7 (2.4) days per week (medically tailored meals) and 5.5 (2.3) days per week (fresh produce), with high retention (96.0%). Fresh produce demonstrated superior acceptability compared with medically tailored meals (Net Promoter Score: 8.6 vs 7.3; P = .02). There was no significant difference in the primary clinical outcome (HF readmission or ED visit) between food supplementation (23 events among 100 participants) vs usual care (9 events among 50 participants) (adjusted rate ratio, 1.09; 95% CI, 0.49-2.43; P = .83). The hierarchical composite favored food supplementation vs usual care (win ratio, 1.21; 95% CI, 1.14-1.29; P < .001). Among participants receiving food supplementation, conditional delivery (vs unconditional) was not associated with risk of HF events. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, 90-day food supplementation was feasible and well accepted in individuals with recent HF. Food supplementation was not associated with an improvement in the primary clinical outcome and there was no difference when conditioning food supplementation on health care engagement. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06115369.
引用
- Pandey, Keshvani, Coellar, et al. Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41949846. doi:10.1001/jamacardio.2026.0435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。